The first biotech out of incubator and investor Jupiter Bioventures is working on a $75 million Series B to bring its first two drug candidates into clinical testing.
Cavalry Biosciences, the first biotech out of incubator and investor Jupiter Bioventures, is working on a $75 million Series B to bring its first two …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
J&J spends $1 billion to enter KRAS race for cancer treatments
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential - Incyte (NASDAQ:INCY
Parabilis sets a record with a $670M biotech IPO
Novo underwhelmed by drug it once fought Pfizer for
Incyte to buy blood disorder drug in possibly $2B deal
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
San Diego's cAMPfield Therapeutics raises $180M Series A backed by Novo Holdings, RA Capital and seven other top-tier life…
If Parabilis follows through with its plans, that would make it one of the largest biotech IPOs of the past few years and the…
Incyte plans to buy Star Therapeutics and its Phase 3 bleeding disorder candidate.
Incyte CEO Bill Meury acquires Vega Therapeutics for up to $2B, adding Phase 3 von Willebrand disease drug as Jakafi faces 2028…
Lilly pays up to $1B for AlzeCure's small-molecule Alzheimer's candidate; Bial drops Parkinson's drug after Phase 2b miss;…
